June 2, 2020 / 10:57 AM / a month ago

BRIEF-Sanofi Says European Commission Approves Sarclisa For Adults

June 2 (Reuters) - Sanofi SA:

* EUROPEAN COMMISSION APPROVES SARCLISA® (ISATUXIMAB) FOR ADULTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

* SARCLISA IN COMBINATION WITH POM-DEX SIGNIFICANTLY REDUCED THE RISK OF PROGRESSION OR DEATH BY 40% VERSUS POM-DEX ALONE

* EC APPROVAL BASED ON DATA FROM FIRST RANDOMIZED PHASE 3 TRIAL (ICARIA-MM) TO REPORT RESULTS EVALUATING AN ANTI-CD38 MONOCLONAL ANTIBODY COMBINED WITH POMALIDOMIDE AND DEXAMETHASONE (POM-DEX) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below